Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$16.54
-3.7%		$17.12
$8.72
▼
$27.41
$610.43M1.24276,275 shs337,885 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.77
+0.5%		$0.83
$0.73
▼
$1.51
$98.57M1.151.26 million shs441,982 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$4.70
+1.6%		$4.49
$2.09
▼
$5.47
$195.31M1.19227,837 shs99,162 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-8.62%-14.06%-1.72%-2.88%+37.44%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-1.44%-3.30%-6.55%-19.92%-39.46%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.00%-3.35%+1.09%+19.07%+101.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$16.54
-3.7%		$17.12
$8.72
▼
$27.41
$610.43M1.24276,275 shs337,885 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$0.77
+0.5%		$0.83
$0.73
▼
$1.51
$98.57M1.151.26 million shs441,982 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$4.70
+1.6%		$4.49
$2.09
▼
$5.47
$195.31M1.19227,837 shs99,162 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-8.62%-14.06%-1.72%-2.88%+37.44%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-1.44%-3.30%-6.55%-19.92%-39.46%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.00%-3.35%+1.09%+19.07%+101.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2.83
Moderate Buy$29.6078.96% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.67
Moderate Buy$5.00546.83% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ONCY, ORMP, and CBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/14/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$27.00
9/8/2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
8/27/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$27.00
8/24/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/19/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.00
8/7/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/16/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/14/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/13/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/25/2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10.84M56.67N/AN/A$14.32 per share1.16
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A($0.04) per shareN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2M97.66$0.09 per share50.92$5.02 per share0.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$153.94M-$6.72N/AN/AN/AN/A-101.50%-86.86%11/5/2026 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$28.76M-$0.34N/AN/AN/AN/A-2,185.97%-442.99%11/11/2026 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$64.05M$4.121.14N/AN/AN/A-5.17%-4.54%11/12/2026 (Estimated)

Latest ONCY, ORMP, and CBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.0538-$0.08-$0.0262-$0.08N/AN/A
8/10/2026Q2 2026
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.43-$0.09-$0.52$1.84N/AN/A
7/30/2026Q2 2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.7357-$0.74-$0.0043-$0.74$0.36 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$0.255.32%N/A6.07%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.66
9.66
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
1.35
1.35
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
12.73%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
24.84%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
20.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4437.14 million27.92 millionNo Data
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
29127.51 million127.38 millionNot Optionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1341.60 million32.96 millionOptionable

Recent News About These Companies

Oramed Pharmaceuticals consensus price target increased 12.00% to $7.14
September 15 at 7:03 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/oramed-pharmaceuticals-consensus-price-target-increased-12-00-to-7-14/ar-AA2chzvw
Q3 EPS Estimate for Oramed Pharmaceuticals Cut by Analyst
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q3-eps-estimate-for-oramed-pharmaceuticals-cut-by-analyst-2026-09-02/
Oramed: Q2 Earnings Snapshot
August 11, 2026  |  chron.comhttps://www.chron.com/business/article/oramed-q2-earnings-snapshot-22382586.php
Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock
July 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ormp-insider-buying-and-selling-2026-07-03/
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-releases-letter-to-shareholders-highlighting-russell-20003000-index-inclusion-scilex-loan-repayment-strategic-portfolio-appreciation-and-a-strengthened-balance-sheet-302810903.html
ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/ormp-view-inclusion-in-russell-indexes-as-positive-that-could-raise-awareness-in-investment-community/ar-AA25Z9Hc
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
June 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes-302803049.html
ORMP: Strategically acquiring interests in medtech & technology companies
June 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/technology/ormp-strategically-acquiring-interests-in-medtech-technology-companies/ar-AA257A8O
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
May 22, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4908089-oramed-pharmaceuticals-oral-insulin-drug-failure-pivot-and-new-strategic-investment-direction
Oramed Pharmaceuticals Inc.
May 18, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/ORMP/financials/cash-flow
Oramed Pharmaceuticals Delays Quarterly SEC Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
Oramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMP
May 15, 2026  |  benzinga.comhttps://www.benzinga.com/quote/ORMP/earnings
Oramed Pharmaceuticals Incorporated
April 15, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/ORMP
Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/oramed-pharmaceuticals-ormp-price-target-increased-by-9231-to-638/ar-AA1Zzec8
Oramed: Q4 Earnings Snapshot
March 26, 2026  |  stamfordadvocate.comS
Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed
March 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68042496-lifeward-ltd-lifeward-successfully-closes-on-strategic-partnership-with-oramed-399.htm
Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability
March 13, 2026  |  quiverquant.comQ
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
March 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/13/3255419/32993/en/lifeward-receives-shareholder-approval-to-close-on-strategic-partnership-with-oramed-creating-diversified-biomedical-company.html
Oramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic Transaction
January 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-01/67423064-oramed-pharmaceuticals-inc-oramed-and-lifeward-announce-strategic-transaction-008.htm
Oramed and Lifeward Announce Strategic Transaction
January 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/oramed-and-lifeward-announce-strategic-transaction-302659575.html
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
January 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/13/3217760/32993/en/lifeward-enters-transformative-strategic-investment-and-partnership-agreement-with-oramed-to-create-a-diversified-biomedical-innovation-company.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$16.54 -0.64 (-3.73%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$0.77 +0.00 (+0.55%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$4.70 +0.08 (+1.62%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas